Moderate
Suspected
描述
Fluoxetine plus sumatriptan may potentiate serotonin syndrome risk, though the clinical evidence is mixed and the absolute risk is debated.
机制
Fluoxetine inhibits serotonin reuptake and is a potent CYP2D6 inhibitor which may modestly increase sumatriptan exposure; combined serotonergic activity raises theoretical serotonin syndrome risk.
临床意义
Post-marketing surveillance reports exist; many clinical guidelines permit the combination with monitoring, given frequent co-prescription in migraine.
处理措施
Combination is commonly used; monitor for signs of serotonin syndrome especially at treatment initiation or dose escalation.